Version 1
: Received: 9 July 2024 / Approved: 10 July 2024 / Online: 11 July 2024 (08:27:23 CEST)
How to cite:
Fernandez, T.; Marconi, C.; Montaño-Castellón, I.; Deminco, F.; BRITES, C. A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Preprints2024, 2024070897. https://doi.org/10.20944/preprints202407.0897.v1
Fernandez, T.; Marconi, C.; Montaño-Castellón, I.; Deminco, F.; BRITES, C. A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Preprints 2024, 2024070897. https://doi.org/10.20944/preprints202407.0897.v1
Fernandez, T.; Marconi, C.; Montaño-Castellón, I.; Deminco, F.; BRITES, C. A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Preprints2024, 2024070897. https://doi.org/10.20944/preprints202407.0897.v1
APA Style
Fernandez, T., Marconi, C., Montaño-Castellón, I., Deminco, F., & BRITES, C. (2024). A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes. Preprints. https://doi.org/10.20944/preprints202407.0897.v1
Chicago/Turabian Style
Fernandez, T., Felice Deminco and CARLOS BRITES. 2024 "A Systematical Review on ART Use in HTLV Infection: Clinical, Virological, and Immunological Outcomes" Preprints. https://doi.org/10.20944/preprints202407.0897.v1
Abstract
Human T-cell lymphotropic virus (HTLV) infection lacks effective treatment. This review describes the virological, immunological and clinical outcomes of antiretroviral therapy (ART) in people with HTLV infection.
This systematic review followed PRISMA reporting guidelines and was registered in PROSPERO: CRD42022350076. The Newcastle-Ottawa Scales, adapted for cross-sectional studies, and Rob-2 were employed to assess the methodological quality of studies. A systematic search was conducted in Medline (PubMed), Scopus (Elsevier), Cochrane Library, and Web of Science (Clarivate Analytics) databases.
We retrieved data from 08 methodologically diverse articles, on treatment of patients infected by HTLV-1 or HTLV-2 alone, or coinfected by HIV-1 with Raltegravir, Tenofovir, Lamivudine and Zidovudine. Proviral load decreased in 3 of 7 studies, during 4 to 48 weeks of antiretrovirals use. Cellular immune response (CD4, CD8, CD25, CD69 and CD71 cells) were evaluated in six studies. There was no significant clinical improvement in the studies but all of them detected clinical stability during treatment.
Despite the demonstrated antiviral activity of ART, in vitro, clinical improvement was not proven. Most studies showed disease stability during ART use, suggesting potential clinical benefits. There is a need of larger, well-controlled trials, to define the role of ART for treatment of HTLV infection.
Keywords
HTLV; Antiretroviral; Treatment
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
